Can-Fitea??s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)

BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology
company with a pipeline of proprietary small molecule drugs that address
cancer, liver and inflammatory diseases, announced today that the
International Liver Cancer Association (ILCA) has accepted Can-Fitea??s
abstract describing the latest data from the Companya??s Phase II Liver
Cancer study of Namodenoson for an oral presentation at its annual
conference. The oral presentation titled "The Safety and Efficacy of
Namodenoson in the Second Line Treatment of Advanced Hepatocellular
Carcinoma (HCC) Patients with Underlying Child-Pugh B (CPB) Liver
Cirrhosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlleda?? will
be delivered on September 22, 2019 during the Novel Targets and
Prognostic Markers Session from 11:00 am to 12:30 pm. The ILCAa??s 13th
Annual Conference will take place from September 20 to 22, 2019 in
Chicago, Illinois.

is the only international organization devoted exclusively to liver
cancer research for experts from all related disciplines. Its mission is
to lead a global community of physicians, scientists and allied
professionals through education and research with the goal to better
prevent and treat liver cancer.

"This is a very prestigious conference that brings together the leading
thought leaders, researchers, and physicians in the treatment of liver
cancer. Governing members of the ILCA thoroughly research each abstract
submission and select those that are most relevant to the advancement of
treating liver cancer. We are pleased that the selection committee sees
the potential of Namodenoson as a treatment for advanced liver cancer
patients with severe liver dysfunction. Based on both safety and
efficacy in this Phase II study, Can-Fite is preparing a Phase III
trial,a?? stated Can-Fite CEO Pnina Fishman.

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high
affinity and selectivity to the A3 adenosine receptor (A3AR).
Namodenoson is being evaluated as a second line treatment for
hepatocellular carcinoma, with a recently completed Phase II trial and
planned Phase III trial in this indication. The drug is currently in an
ongoing Phase II trial as a treatment for non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly
expressed in diseased cells whereas low expression is found in normal
cells. This differential effect accounts for the excellent safety
profile of the drug.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2020    »